Three distinct phase II trials assessed the role of protein-kinase inhibitors (PKI) as adjuvant drugs in recurrent, surgery- and radiation-refractory WHO grade 1–3 meningiomas [36,42,44]. This evidence concerns the gene WEE1 and meningioma.